Maplight is a biopharmaceutical company discovering and developing novel therapeutics for patients with disorders of the central nervous system (CNS).
Location: United States, California, Palo Alto
Employees: 11-50
Total raised: $225M
Founded date: 2018
Investors 1
Funding Rounds 1
| Date | Series | Amount | Investors |
| 30.10.2023 | Series C | $225M | - |
Mentions in press and media 6
| Date | Title | Description |
| 06.11.2025 | Beta Technologies Soars with Billion-Dollar IPO, Redefining Electric Aviation | Electric aircraft innovator Beta Technologies completed a massive IPO. It raised over $1 billion. The company sold 29.9 million shares. Pricing hit $34 per share. This valued the Vermont-based firm at approximately $7.4 billion. Its NYSE de... |
| 04.11.2025 | Американский производитель электросамолетов Beta Technologies привлек $1 млрд в ходе IPO | Согласно заявлению, опубликованному в понедельник (которое подтвердило более ранний отчет Bloomberg News), акции были размещены по $34 за штуку, что выше маркетингового диапазона. Объем размещения был увеличен до 29,9 млн акций по сравнению... |
| 22.09.2025 | Big Pharma-backed MapLight plots IPO to advance neuro pipeline | MapLight Therapeutics has illuminated a path toward an initial public offering, filing with the Securities and Exchange Commission (SEC) on Sept. 19 to be listed on the Nasdaq under the ticker symbol "MPLT." Should the IPO go thro... |
| 28.07.2025 | MapLight Therapeutics Raises $372.5M in Series D Funding | MapLight Therapeutics, a Redwood City, CA-based clinical-stage biopharmaceutical company, raised $372.5M in Series D financing. The round was led by Forbion and Life Sciences at Goldman Sachs Alternatives, with participation from additional... |
| 28.03.2024 | MAPLIGHT THERAPEUTICS ANNOUNCES INITIATION OF PHASE 1 CLINICAL TRIAL FOR ML-007/PAC, UNDER DEVELOPMENT FOR SCHIZOPHRENIA AND ALZHEIMER'S DISEASE PSYCHOSIS | Study to evaluate safety and tolerability of extended-release fixed dose combination ML-007/PAC with precision-matched release kinetics in advance of planned Phase 2 clinical trials ML-007/PAC dosing regimens to be assessed in healthy non-e... |
| 30.10.2023 | MapLight Therapeutics Closes $225M Series C Funding | MapLight Therapeutics, a San Francisco, CA-based clinical-stage biopharmaceutical company, raised $225M in Series C funding. The round was led by Novo Holdings, 5AM Ventures, Cowen Healthcare Investments and other investors. In connection w... |